Search
Hyaluronidase (human recombinant)
A purified preparation of the enzyme recombinant human hyaluronidase. Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase is an enzym...
Human immunoglobulin G
go.drugbank.com/drugs/DB00028ApprovedInvestigationalIVIg contains the same distribution of IgG antibody subclasses as is found in the general human population. … Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation.
Categories: Human Immunoglobulin GSynonyms: Human IGG, Human gammaglobulinPegvorhyaluronidase alfa
go.drugbank.com/drugs/DB14912InvestigationalPegvorhyaluronidase alfa is under investigation in clinical trial NCT02241187 (Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection).
Synonyms: PEGylated recombinant human hyaluronidase PH20, HUMAN HYALURONIDASE PH-20 (HYALURONOGLUCOSAMINIDASE PH-20, SPERM ADHESION MOLECULE 1, EC 3.2.1.35) PRECURSOR-(36-482)-PEPTIDE (MATURE (1-447)-PEPTIDE), PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORMBerahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalBerahyaluronidase alfa is a recombinant variant of human hyaluronidase designed to enhance dispersion and permeation of subcutaneously co-administered drugs.
Categories: Hyaluronidases, Recombinant ProteinsEfgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigational[L43190] A formulation for subcutaneous use that combines efgartigimod alfa and hyaluronidase was later approved for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP
Categories: Human Immunoglobulin GDaratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigational[L13290,L13296] A subcutaneous formulation of daratumumab co-formulated with hyaluronidase-fihj is also approved for the treatment of adults with multiple myeloma.
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalPertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2).
Categories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsOcrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigational[A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA. … The addition of hyaluronidase allows for subcutaneous injection, which is a method often preferable for patients and provides an alternative means of administration for sites lacking IV infrastructure,
Trastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationaldomain of the human epidermal growth factor receptor protein (HER2). … Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody [A40276] that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular
Categories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsRituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalThe antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences. … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.